| Symbol | AGMB |
|---|---|
| Name | AGOMAB THERAPEUTICS NV |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | POSTHOFLEI 1/6, ANTWERPEN, 2600, Belgium |
| Telephone | +32 3318 9170 |
| Fax | — |
| — | |
| Website | www.agomab.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001213900-26-044365 <b>Size:</b> 20 KB
Read moreAgomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030840 <b>Size:</b> 11 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030842 <b>Size:</b> 14 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030843 <b>Size:</b> 24 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030839 <b>Size:</b> 13 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030838 <b>Size:</b> 13 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030837 <b>Size:</b> 22 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030833 <b>Size:</b> 18 KB
Read moreNew Form 3 - Agomab Therapeutics NV <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030841 <b>Size:</b> 15 KB
Read more